Blair William & Co. IL Sells 9,488 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Blair William & Co. IL lowered its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 2.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 420,305 shares of the company’s stock after selling 9,488 shares during the quarter. Blair William & Co. IL owned about 0.81% of PROCEPT BioRobotics worth $25,676,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of PRCT. Quest Partners LLC boosted its holdings in PROCEPT BioRobotics by 2,492.3% in the 2nd quarter. Quest Partners LLC now owns 674 shares of the company’s stock valued at $41,000 after purchasing an additional 648 shares during the period. Fairman Group LLC acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $84,000. RiverPark Advisors LLC bought a new stake in shares of PROCEPT BioRobotics in the second quarter valued at approximately $135,000. nVerses Capital LLC grew its position in PROCEPT BioRobotics by 300.0% during the second quarter. nVerses Capital LLC now owns 2,400 shares of the company’s stock worth $147,000 after buying an additional 1,800 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new position in PROCEPT BioRobotics during the 2nd quarter worth $284,000. Institutional investors own 89.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PRCT. Bank of America upped their target price on PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Wells Fargo & Company boosted their price target on PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. TD Cowen increased their price objective on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Truist Financial boosted their price objective on shares of PROCEPT BioRobotics from $74.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $78.17.

PROCEPT BioRobotics Stock Up 4.0 %

PRCT stock opened at $82.97 on Thursday. The stock has a market capitalization of $4.31 billion, a P/E ratio of -39.14 and a beta of 1.03. The company has a current ratio of 7.51, a quick ratio of 6.49 and a debt-to-equity ratio of 0.20. The firm has a 50-day moving average price of $70.63 and a 200-day moving average price of $62.14. PROCEPT BioRobotics Co. has a 12 month low of $24.83 and a 12 month high of $85.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.02. The business had revenue of $53.35 million during the quarter, compared to the consensus estimate of $50.10 million. PROCEPT BioRobotics had a negative net margin of 58.73% and a negative return on equity of 37.85%. The firm’s revenue was up 61.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.56) EPS. As a group, equities research analysts anticipate that PROCEPT BioRobotics Co. will post -1.88 EPS for the current fiscal year.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 44,867 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $80.11, for a total value of $3,594,295.37. Following the completion of the transaction, the director now owns 197,453 shares of the company’s stock, valued at approximately $15,817,959.83. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO Kevin Waters sold 25,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $82.51, for a total transaction of $2,062,750.00. Following the completion of the transaction, the chief financial officer now owns 96,096 shares of the company’s stock, valued at $7,928,880.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Antal Rohit Desai sold 44,867 shares of PROCEPT BioRobotics stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $80.11, for a total transaction of $3,594,295.37. Following the transaction, the director now owns 197,453 shares in the company, valued at approximately $15,817,959.83. The disclosure for this sale can be found here. Insiders have sold a total of 154,892 shares of company stock valued at $12,134,665 in the last 90 days. 17.40% of the stock is owned by corporate insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).